MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 328610 | Name: Mesalamine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mesalamine, also known as Asacol and 5-ASA, is an IkB kinase inhibitor structurally related to the salicylates, which is active in inflammatory bowel disease. Mesalamine is used in the treatment of ulcerative colitis.

Chemical Structure

Mesalamine
CAS#89-57-6

Theoretical Analysis

MedKoo Cat#: 328610

Name: Mesalamine

CAS#: 89-57-6

Chemical Formula: C7H7NO3

Exact Mass: 153.0426

Molecular Weight: 153.14

Elemental Analysis: C, 54.90; H, 4.61; N, 9.15; O, 31.34

Price and Availability

Size Price Availability Quantity
25g USD 250.00 2 Weeks
100g USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Mesalamine; Asacol; Z-206; 5-ASA; AJG-501; MAX-002; Z 206; 5 ASA; AJG 501; MAX 002; Z206; 5ASA; AJG501; MAX002
IUPAC/Chemical Name
5-amino-2-hydroxybenzoic acid
InChi Key
KBOPZPXVLCULAV-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
SMILES Code
O=C(O)C1=CC(N)=CC=C1O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C23B03B17
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
In vitro activity:
Because peroxynitrite has been critically involved in inflammatory stress and carcinogenesis, this study was undertaken to investigate the effects of 5-ASA (5-aminosalicylic acid) in peroxynitrite-induced DNA strand breaks, an important event leading to peroxynitrite-elicited cytotoxicity. The presence of 5-ASA at 0.1 and 1.0 mM was found to significantly inhibit SIN-1-induced DNA strand breaks in a concentration-dependent manner. Reference: Mol Cell Biochem. 2013 Jun;378(1-2):291-8. https://pubmed.ncbi.nlm.nih.gov/23529546/
In vivo activity:
The antineoplastic effect of 5-ASA (5-aminosalicylic acid) was evaluated in a xenograft tumor model in SCID mice and in azoxymethane (AOM)-induced colon carcinogenesis in A/JOlaHsd mice. In the xenograft model, GW9662 abolished the therapeutic effect of 5-ASA, which decreased tumor weight and volume by 80% in SCID mice compared with untreated mice. In A/JOlaHsd mice, 5-ASA suppressed colon carcinogenesis by decreasing the number of aberrant crypt foci (75%) and aberrant crypts (22%) induced by AOM treatment with an absence of 5-ASA response after GW9662 administration. Reference: Carcinogenesis. 2013 Nov;34(11):2580-6. https://pubmed.ncbi.nlm.nih.gov/23843037/
Solvent mg/mL mM comments
Solubility
DMF 1.6 10.45
DMSO 13.7 89.24
Ethanol 31.0 202.43
PBS (pH 7.2) 1.7 11.10
Water 2.0 13.06
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 153.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Graham PM, Li JZ, Dou X, Zhu H, Misra HP, Jia Z, Li Y. Protection against peroxynitrite-induced DNA damage by mesalamine: implications for anti-inflammation and anti-cancer activity. Mol Cell Biochem. 2013 Jun;378(1-2):291-8. doi: 10.1007/s11010-013-1620-z. Epub 2013 Mar 26. PMID: 23529546. 2. Khare V, Lyakhovich A, Dammann K, Lang M, Borgmann M, Tichy B, Pospisilova S, Luciani G, Campregher C, Evstatiev R, Pflueger M, Hundsberger H, Gasche C. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol. 2013 Jan 15;85(2):234-44. doi: 10.1016/j.bcp.2012.10.026. Epub 2012 Nov 9. PMID: 23146664; PMCID: PMC3557386. 3. Cannon AR, Akhtar S, Hammer AM, Morris NL, Javorski MJ, Li X, Kennedy RH, Gamelli RL, Choudhry MA. Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury. J Burn Care Res. 2016 Sep-Oct;37(5):283-92. doi: 10.1097/BCR.0000000000000396. PMID: 27388883; PMCID: PMC5014636. 4. Rousseaux C, El-Jamal N, Fumery M, Dubuquoy C, Romano O, Chatelain D, Langlois A, Bertin B, Buob D, Colombel JF, Cortot A, Desreumaux P, Dubuquoy L. The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ. Carcinogenesis. 2013 Nov;34(11):2580-6. doi: 10.1093/carcin/bgt245. Epub 2013 Jul 10. PMID: 23843037; PMCID: PMC3810841.
In vitro protocol:
1. Graham PM, Li JZ, Dou X, Zhu H, Misra HP, Jia Z, Li Y. Protection against peroxynitrite-induced DNA damage by mesalamine: implications for anti-inflammation and anti-cancer activity. Mol Cell Biochem. 2013 Jun;378(1-2):291-8. doi: 10.1007/s11010-013-1620-z. Epub 2013 Mar 26. PMID: 23529546. 2. Khare V, Lyakhovich A, Dammann K, Lang M, Borgmann M, Tichy B, Pospisilova S, Luciani G, Campregher C, Evstatiev R, Pflueger M, Hundsberger H, Gasche C. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol. 2013 Jan 15;85(2):234-44. doi: 10.1016/j.bcp.2012.10.026. Epub 2012 Nov 9. PMID: 23146664; PMCID: PMC3557386.
In vivo protocol:
1. Cannon AR, Akhtar S, Hammer AM, Morris NL, Javorski MJ, Li X, Kennedy RH, Gamelli RL, Choudhry MA. Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury. J Burn Care Res. 2016 Sep-Oct;37(5):283-92. doi: 10.1097/BCR.0000000000000396. PMID: 27388883; PMCID: PMC5014636. 2. Rousseaux C, El-Jamal N, Fumery M, Dubuquoy C, Romano O, Chatelain D, Langlois A, Bertin B, Buob D, Colombel JF, Cortot A, Desreumaux P, Dubuquoy L. The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ. Carcinogenesis. 2013 Nov;34(11):2580-6. doi: 10.1093/carcin/bgt245. Epub 2013 Jul 10. PMID: 23843037; PMCID: PMC3810841.
1: Rehman F, Rahim A, Airoldi C, Volpe PL. Preparation and characterization of glycidyl methacrylate organo bridges grafted mesoporous silica SBA-15 as ibuprofen and mesalamine carrier for controlled release. Mater Sci Eng C Mater Biol Appl. 2016 Feb;59:970-9. doi: 10.1016/j.msec.2015.11.005. Epub 2015 Nov 4. PubMed PMID: 26652455. 2: Andreas CJ, Chen YC, Markopoulos C, Reppas C, Dressman J. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release. Eur J Pharm Biopharm. 2015 Nov;97(Pt A):39-50. doi: 10.1016/j.ejpb.2015.09.002. Epub 2015 Sep 21. PubMed PMID: 26391972. 3: Torkashvand M, Gholivand MB, Taherkhani F. Fabrication of an electrochemical sensor based on computationally designed molecularly imprinted polymer for the determination of mesalamine in real samples. Mater Sci Eng C Mater Biol Appl. 2015 Oct;55:209-17. doi: 10.1016/j.msec.2015.05.031. Epub 2015 May 10. PubMed PMID: 26117757. 4: Boyle M, Ting A, Cury DB, Nanda K, Cheifetz AS, Moss A. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015 Dec;21(12):2873-8. doi: 10.1097/MIB.0000000000000562. PubMed PMID: 26313693. 5: OʼConnor A, Packey CD, Akbari M, Moss AC. Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov;21(11):2562-9. doi: 10.1097/MIB.0000000000000540. Review. PubMed PMID: 26296062. 6: Neufeld L, Bianco-Peled H. Designing a biocompatible hydrogel for the delivery of mesalamine. Int J Pharm. 2015 Aug 1;491(1-2):170-9. doi: 10.1016/j.ijpharm.2015.06.026. Epub 2015 Jun 23. PubMed PMID: 26116013. 7: Baker WL, Saulsberry WJ, Elliott K, Parker MW. Cardiac MRI-confirmed mesalamine-induced myocarditis. BMJ Case Rep. 2015 Sep 4;2015. pii: bcr2015210689. doi: 10.1136/bcr-2015-210689. PubMed PMID: 26341161. 8: Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Dig Dis Sci. 2016 Jan;61(1):221-9. doi: 10.1007/s10620-015-3866-7. Epub 2015 Nov 12. PubMed PMID: 26563167; PubMed Central PMCID: PMC4700064. 9: Tenjarla S. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels. Drugs R D. 2015 Jun;15(2):211-5. doi: 10.1007/s40268-015-0097-5. PubMed PMID: 26115756; PubMed Central PMCID: PMC4488180. 10: Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1444-9.e1. doi: 10.1016/j.cgh.2015.02.019. Epub 2015 Feb 24. PubMed PMID: 25724700. 11: Zakko SF, Gordon GL, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. Postgrad Med. 2016;128(3):273-81. doi: 10.1080/00325481.2016.1152876. Epub 2016 Mar 1. PubMed PMID: 26861051. 12: Nespoli L, Lo Bianco G, Uggeri F, Romano F, Nespoli A, Bernasconi DP, Gianotti L. Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis. World J Gastroenterol. 2015 Jul 21;21(27):8366-72. doi: 10.3748/wjg.v21.i27.8366. PubMed PMID: 26217088; PubMed Central PMCID: PMC4507106. 13: Abinusawa A, Tenjarla S. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels. Adv Ther. 2015 May;32(5):477-84. doi: 10.1007/s12325-015-0206-4. Epub 2015 May 8. PubMed PMID: 25951927; PubMed Central PMCID: PMC4449368. 14: Moss AC, Lillis Y, Edwards George JB, Choudhry NK, Berg AH, Cheifetz AS, Horowitz G, Leffler DA. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014 Dec;109(12):1850-5. doi: 10.1038/ajg.2014.158. Epub 2014 Jun 10. PubMed PMID: 24913040. 15: Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD; DEAR Investigators. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1887-93.e3. doi: 10.1016/j.cgh.2014.03.035. Epub 2014 Apr 30. PubMed PMID: 24793028; PubMed Central PMCID: PMC4214893.

View History

Benzquinamide Free Base

Benzquinamide Free Base